OneSource Speciality Pharma shares jump over 3% on securing EU GMP certificate for SPD facility

Shares of OneSource Speciality Pharma rallied over 4% on Wednesday morning after the company secured an EU GMP certificate for the SPD facility. The shares opened at an intraday high level of ₹1,840 apiece on the NSE. The speciality Pharma company was

OneSource Speciality Pharma has received an EU GMP Certificate of Compliance of a Manufacturer for its Sterile Product Division (SPD) facility from the competent German authority, the State Office for Occupational Safety, Social Affairs and Health of Schleswig-Holstein, Germany. The certificate, dated April 27, 2026, was issued following the latest inspection conducted on October 14, 2025, and confirms compliance with EU GMP requirements for sterile products. The certificate covers sterile products, including aseptically prepared small volume liquids, secondary packing and quality control testing.

Separately, the Sterile Product Division has capabilities across liquid vials, lyophilised vials, pre-filled syringes and autoinjectors, and holds approvals from US-FDA, Health Canada, ANVISA and TGA.

Earlier this month, the company announced that its partner Orbicular Pharmaceutical Technologies (“Orbicular”), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval for an Abbreviated New Drug Application (ANDA) for a generic version of Ozempic® (Semaglutide Injection).

OneSource Speciality Pharma Limited is a pure-play speciality pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products, including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatin capsules).

It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource, with its development capabilities, industry-leading manufacturing capacities, and strong compliance track record, has won the trust of global pharmaceutical companies seeking efficient, end-to-end solutions